The Global Ribonucleic Acid (RNA) Markers Market is estimated to be valued at US$ 226.6 Mn in 2023 and is expected to exhibit a CAGR of 8.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
RNA markers help detect diseases through the analysis of RNA levels in the body. They are useful biomarkers of diseases since RNA levels can indicate abnormal gene expression associated with various disease conditions. Advances in RNA extraction technologies and sequencing have expanded the utility of RNA markers in clinical diagnostics.
Market key trends:
One of the key trends in the RNA markers market is the increasing focus on non-coding RNAs (ncRNAs) as biomarkers. While most genetic research has focused on protein-coding genes, it is now known that ncRNAs, such as microRNAs and long non-coding RNAs, play important regulatory roles in various biological processes. Several studies have identified specific ncRNAs that show potential as clinically useful biomarkers for cancers and other diseases. For example, certain microRNAs have shown promise as biomarkers for prostate cancer, melanoma, and Alzheimer’s disease. The identification of more ncRNAs linked to human diseases is expected to boost the development of ncRNA-based biomarkers.
The global RNA markers market is segmented based on analysis technique, product type, and application. Under analysis technique, quantitative polymerase chain reaction (qPCR) dominates the market as it offers high sensitivity and specificity for RNA quantification. qPCR is the most widely used technique for the detection and quantification of RNA markers.
The Global Ribonucleic Acid (Rna) Markers Market Analysis is expected to witness high growth, exhibiting CAGR of 8.7% over the forecast period, due to increasing prevalence of cancer and other chronic diseases. Regional analysis – North America dominates the global RNA markers market owing to growing R&D investment and technological advancements in the region. The Asia Pacific region is expected to witness fastest growth over the forecast period due to rising healthcare expenditure.
Key players operating in the Ribonucleic Acid (RNA) Markers Market are Agilent Technologies, Inc., Oxford Gene Technology IP Limited, PerkinElmer Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd, NextGen Life Sciences Private Limited, bioMérieux SA, New England Biolabs, Promega Corporation, Merck KGaA, Takara Bio Inc., Abnova Corporation, Thermo Fisher Scientific Inc., QIAGEN, Bio-Rad Laboratories, Inc., Lonza, CardioNet, ZOLL Medical Corporation and Hill-Rom Services, Inc.